赛生医药(中国)有限公司

SciClone is a US-based, China-focused specialty pharmaceutical company with a substantial revenue-generating and profitable commercial business and a broad, marketed product portfolio of differentiated therapies for oncology, infectious diseases and cardiovascular disorders.

赛生公司是总部设于美国、以中国为中心的专业制药公司，具有相当的商业规模且盈利丰厚，上市产品种类丰富，用于治疗肿瘤、传染性疾病和心血管、泌尿、呼吸、及中枢神经系统的各种病症。

SciClone’s proprietary lead product, ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical partners, SciClone markets multiple branded products in China which are therapeutically differentiated. The Company has successfully in-licensed products with the potential to become future market leaders and to drive the Company’s long-term growth. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN.

赛生的日达仙®（胸腺法新）已在30多个国家获得各种治疗相关适应症的批准。根据不同地区监管机构的批准，这些适应症包括可以用于疫苗佐剂，或用于治疗乙型肝炎（HBV）和丙型肝炎（HCV），以及某些癌症。除日达仙®以外，赛生在中国还拥有其他14种产品，其中大部分为合作产品，包括使用最为广泛的广谱抗癫痫处方药德巴金®；用于高血压治疗的ACE抑制剂瑞泰®；用于失眠症短期治疗的速效安眠药思诺思®（在美国以安比恩®商标销售）；以及近期投放市场的心血管病介入产品艾卡特®。赛生同时还正在中国申请注册其他治疗领域产品。赛生的总部 位于 美国 加利福尼亚州的福斯特城。